The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
27-May-25
$100 million
Target:
Emergency Care Partners
Advised Emergency Care Partners (“ECP”), a leading provider of emergency department management services and its majority owner Varsity Healthcare Partners (“VHP”) on a growth recapitalization transaction, inclusive of a $100 million preferred equity investment led by MidOcean Partners (“MidOcean”)
08-May-25
Undisclosed
Target:
German Doner Kebab ("GDK")
Acquiror:
True
Advised Hero Brands on the strategic investment in GDK by True. GDK is a leading Middle Eastern quick-service restaurant brand, with over 145 franchised locations in the UK and 170 globally, including the US, Canada, Sweden and the Middle East
05-May-25
Pending
~$10 billion
Target:
Skechers U.S.A., Inc.
Acquiror:
3G Capital
Advising Skechers, the third largest footwear company in the world, on its sale to 3G Capital
17-Mar-25
Pending
$535 million
Target:
Notified
Acquiror:
Equiniti Group (a Siris Capital Group portfolio company)
Advising Equiniti Group, a Siris Capital Group portfolio company, on the acquisition of the Notified, a wholly owned subsidiary of West Technology Group., an Apollo Global Management portfolio company
04-Feb-25
Pending
$1.1 billion
Target:
PRISM Vision Group
Acquiror:
McKesson Corporation
Advising PRISM Vision Group, a leading medical eye care services company, on its majority stake sale to McKesson Corporation, a diversified healthcare services and distribution leader
28-Jan-25
$219 million
Target:
The Container Store, Inc.
Advised the Ad Hoc Group of Term Loan Lender to The Container Store on its Pre Packaged Chapter 11 Restructuring
24-Dec-24
Undisclosed
Target:
Ex-US rights to branded narcolepsy treatments, Provigil® (modafinil) and Nuvigil® (armodafinil)
Acquiror:
Neuraxpharm Group
Advised Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company, on the acquisition of the ex-US rights to Provigil® (modafinil) and Nuvigil® (armodafinil) from Teva Pharmaceuticals Industries Ltd. (“Teva”)
12-Dec-24
$460 million
Target:
Brigit
Acquiror:
Upbound Group
Advised Upbound Group, a technology and data-driven leader in accessible and inclusive financial products that address the evolving needs and aspirations of underserved consumers, on its acquisition of Brigit, a leading financial health technology company
27-Nov-24
$618 million
Target:
Empire Today
Advised Empire Today, the largest and only national DTC provider of replacement hard surface flooring and carpet in the U.S., on its liability management transaction
14-Nov-24
$263 million
Target:
Robertet SA
Acquiror:
Fonds Stratégique de Participations and Peugeot Invest SA
Advising Fonds Stratégique de Participations and Peugeot Invest SA, on the acquisition of a 14% stake for €250 million in Robertet SA, world leader in natural products, from DSM-Firmenich AG
13-Nov-24
Pending
Undisclosed
Target:
Centogene GmbH
Acquiror:
Charme Capital Partners
Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of pharmaceutical solutions and diagnostic tests for rare diseases
13-Nov-24
Pending
$12.1 billion
Target:
Blue Owl Technology Finance Corp. II (“OTF II”)
Acquiror:
Blue Owl Technology Finance Corp. (“OTF”)
Advised and provided a fairness opinion to the Special Committee of the Independent Directors of OTF II, a specialty finance company focused on originating and making loans to, and making debt and equity investment in, technology related companies, specifically software, based primarily in the US, on its merger with OTF
30-Sep-24
Undisclosed
Target:
Golub Capital LLC
Acquiror:
Mizuho Bank, Ltd.
Advising Mizuho Bank, Ltd., the banking arm of Mizuho Financial Group, Inc., on its purchase of a passive, non-voting minority stake in Golub Capital’s management companies
19-Sep-24
$550 million
Target:
Tacora Resources, Inc.
Acquiror:
O’Brien-Staley Partners, Millstreet Capital Management LLC, Brigade Capital Management LP, Cargill Incorporated
Advised Tacora Resources, a high-grade iron ore producer in Canada, on its CCAA Sale Process and Restructuring of $550 million of liabilities
01-Jul-24
Undisclosed
Target:
Medical Review Institute of America
Acquiror:
Parthenon Capital
Advised Medical Review Institute of America, a portfolio company of Summit Partners and a leading provider of outsourced utilization management and clinical review solutions to payors, on its strategic growth investment from Parthenon Capital
26-Jun-24
Pending
$630 million
Target:
Haleon plc’s Nicotine Replacement Therapy Business (ex-US)
Acquiror:
Dr. Reddy’s Laboratories
Advising Haleon plc on the sale of its global nicotine replacement therapy business (ex-US) to Dr. Reddy’s Laboratories
20-Jun-24
Pending
$1.8 billion
Target:
CP Kelco
Acquiror:
Tate & Lyle
Advising Tate & Lyle plc, a UK-listed specialty food and beverage ingredients company, on the acquisition of CP Kelco, a US-based provider of pectin, speciality gums and other nature-based ingredients, from J.M. Huber Corporation
08-May-24
$800 million
Target:
U.S. Acute Care Solutions
Advised U.S. Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on the refinancing of its senior secured notes
06-May-24
Pending
Undisclosed
Target:
Veen Bosch & Keuning
Acquiror:
Simon & Schuster
Advising Veen Bosch & Keuning, the largest book publisher in the Netherlands, on its sale to Simon & Schuster, one of the world’s preeminent publishing houses
01-May-24
Undisclosed
Target:
Functional Formularies
Acquiror:
Danone
Advised Danone on its acquisition of Functional Formularies, a leading whole foods tube feeding business in the US, from Swander Pace Capital
20-Feb-24
$1.9 billion
Target:
Audacy Inc.
Advising 1L Ad Hoc Group on the pre-packaged restructuring of Audacy, one of the largest multi-platform audio content and entertainment companies with 221 radio stations in 45 distinct markets
16-Nov-23
~$400 million
Target:
Sonoma-Cutrer Vineyards (Brown-Forman)
Acquiror:
The Duckhorn Portfolio
Advised Brown-Forman, the largest American-owned spirits and wine company, on its sale of Sonoma-Cutrer Vineyards to The Duckhorn Portfolio
27-Sep-23
Undisclosed
Target:
Slayback Pharma LLC
Acquiror:
Azurity Pharmaceuticals
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
04-Sep-23
Pending
$6.6 billion AUD
Target:
Liontown Resources Limited
Acquiror:
Albemarle Corporation
Advising Australian-based lithium company Liontown Resources Limited on its response to change of control proposals from Albemarle Corporation
08-Aug-23
Pending
Undisclosed
Target:
Farmalider Group
Acquiror:
MCH
Advising the shareholders of Grupo Farmalider, a B2B Spanish pharmaceutical company focused on contract manufacturing, innovation and development of products based on generics, on the sale of an undisclosed stake to local private equity MCH